Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 – IT Business Net
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care) 1 Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing Basel, December 14, 2020 — Novartis today a...
Source: itbusinessnet.com